---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023059"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2026-05-14T20:05:17+00:00"
generated_at: "2026-05-14T21:01:58.880211+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q1 2026 revenue $0.15M; net loss $9.1M; advances India regulatory milestones

## Summary
- Revenue $0.15M vs $0.05M in Q1 2025; operating loss $9.2M vs $8.6M.
- Net loss $9.1M ($4.06/share) vs $7.5M ($7.05/share); adjusted EBITDA loss $8.7M.
- Cash $8.2M at Mar 31, 2026, down from $11.9M at Dec 31, 2025.
- Received CDSCO license for CoSara PCR Pro instrument in India; ISO 13485 certification for manufacturing facility.
- Completed enrollment in upper respiratory test clinical study with >1,400 patients; advancing TB study in India.

## SEC filing metadata
- accession: 0001493152-26-023059
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2026-05-14T20:05:17+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/0001493152-26-023059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023059
- JSON: https://secwatch.observer/filing/0001493152-26-023059.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023059.txt

## Key facts
- Earnings Releases
  Co-Diagnostics, Inc. reported first quarter ended March 31, 2026 results: revenue $0.15 million, net income Net loss of $9.1 million, or $4.06 per share, EPS $4.06 per share.
  - Period: first quarter ended March 31, 2026
  - Revenue: $0.15 million
  - Net income: Net loss of $9.1 million, or $4.06 per share
  - EPS: $4.06 per share
  - Result: reported results
  source text: global stakeholders ● Expanded the intellectual property portfolio with the issuance of a new international patent in Japan First Quarter 2026 Financial Results: ● Revenue of $0.15 million, compared to $0.05 million in the first quarter of 2025 ● Operating expenses of $9.2 million, compared to $8.6 million in the same period last year, driven by research and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/0001493152-26-023059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.